Martindale Pharma Launches First Ready-To-Use Presentation of Phenylephrine

WOOBURN GREEN, England, April 12, 2016 /PRNewswire/ --

Available In New Presentation Strength of 0.1mg/ml. to Maximise Accuracy and Flexibility of Dosing

Martindale Pharma, the UK-based leading international specialty pharmaceutical company, today announced the UK launch of Phenylephrine, a new strength of the selective vasopressor drug for the treatment of hypotension associated with anaesthesia. From today, Phenylephrine will be available in a 10ml ampoule at a strength of 0.1mg/ml.

This new strength not only allows for accurate dose dispensing but also provides healthcare professionals with a much needed replacement to using the concentrated alternative. To date Phenylephrine is only available as a 10mg/ml in 1ml ampoules, which is diluted prior to use. Martindale Pharma's Phenylephrine product offers a simpler approach to product use, and can be given as an intravenous bolus injection or as a continuous infusion without the need for dilution.

Martindale Pharma has licensed exclusive rights to a range of Phenylephrine products for the UK and Gulf Co-Operation Council Countries from Unimedic AB, Martindale Pharma's strategic partner for Scandinavia. This particular product joins the range of cardiovascular drugs within Martindale Pharma's Emergency Care portfolio.

Michael Clark, Chief Marketing Officer of Martindale Pharma, commented: "We are pleased with this positive addition to this well-known Phenylephrine range. Our novel presentation removes the need to dilute the drug prior to use allowing for more accurate dose dispensing resulting in both time and cost savings for the NHS. Our NHS price is also significantly lower than the "concentrate" product.

The launch of this ready-to-use product demonstrates Martindale Pharma commitment to providing high quality innovative products to our customers and to patients while ensuring cost-effectiveness for the NHS."

For further information on these products please contact customer services on 0800-0287933 or at [email protected], or for medical enquiries please contact medical information at [email protected].

View the Summary of Product Characteristics

https://www.medicines.org.uk/emc/medicine/31686

Notes to editors 

About Martindale Pharma^®  

Martindale Pharma is a leading UK-based, international specialty pharmaceutical company providing essential medicines to over 28 countries around the world.

Our strategy is to build leading positions in defined business segments where there is a high unmet medical need and a demand for improved product presentations. Our focus is on Opioid Addiction, Emergency Care, Hospital-initiated Medicines, Ophthalmics and Unlicensed Medicines (also called "Specials").

With a strong UK presence with expertise in marketing hospital and specialty medicines, Martindale Pharma is recognised as a strategic partner to the NHS and other healthcare providers and supplying over 100 licensed products and with a track record of successful new specialty product launches.

The business also includes a rapidly growing international organisation currently centred on three geographical regions: Saudi Arabia and the Gulf Co-Operation Council territory, Australia and South East Asia and Northern Europe (focused on Scandinavia).

Martindale's supply chain is underpinned by our own modern, efficient UK manufacturing facility which enables us to develop and compete globally to supply high quality, specialty pharmaceuticals in sterile injection and oral liquid formats.

For further information visit our new website http://www.martindalepharma.co.uk

About Unimedic AB 

Unimedic Pharma is a Swedish pharmaceutical company focusing on the Nordic market, providing a wide range of non-licensed, extemporanious and licensed pharmaceuticals based on the needs and requirements from the healthcare professionals.

The Unimedic Group has many years of experience and extensive expertise within the manufacturing, development, distribution, sales and marketing of pharmaceuticals. The company is, today, one of the fastest growing pharmaceutical companies within the Nordic market and has, over the past three years, increased the turnover from MSEK 100 to MSEK 600. The founding of a district laboratory in Matfors in the mid-1960s was the start of pharmaceutical operations.

For further information visit: http://www.unimedic.se/en/

Media contacts:

Martindale Pharma
Michael Clark
Tel: +44(0)1628-551934

Hume Brophy
Mary Clark, Hollie Vile, Elle Kress
Tel: +44(0)207-862-6390

SOURCE Martindale Pharma